Healz Raises €500,000 in a Round Led by The Lab Ventures

Healz, the Valencian company specializing in digital health, which anticipates problems related to chronic metabolic diseases, has raised half a million euros in a round led by The Lab Ventures, a Spanish fund specialized in creating and financing disruptive technology companies, according to Jorge Ruiz, CEO. Likewise, the company will seek to make the leap to Latin America in the coming months.

In the round, in addition to The Lab Ventures, small investors linked to the health sector and a former first-division soccer player, whose name has not been released, have also participated. The company will use the resources to advance in the development of its technological platform, search for new functionalities and make the international leap. Lab Ventures has previously invested in Healz, with a contribution of €850,000.

Healz has a Software as a Service (SaaS) health and lifestyle platform. The company is aware that most chronic metabolic diseases are caused by a bad lifestyle and early diagnosis is difficult.

Healz helps to understand how the metabolism reacts to lifestyle (food, exercise, stress, and rest). The platform is made up of a SaaS aimed at the doctor and an app for the patient, which are interrelated and offer information of interest to both. Clients can be from individuals to professional athletes.

Read more about Healz and find the most important business news of the day with the Born2Invest mobile app.

Healz is working on future integrations such as basic hormone and microbiota analytics

The SaaS generates detailed reports to be interpreted by the professional and contains a CRM that facilitates the management of the practice and improves the patient experience. On the other hand, the app informs the end user of the metabolic state in a simple and summarized way and offers the possibility of making an online consultation with a professional.

To assess the user’s metabolic state, Healz connects to a continuous glucose monitoring (CGM) sensor and various wearables. The company is working on future integrations such as the basic analysis of hormones and microbiota, with which it is intended to carry out a 360-degree sweep of the symptoms related to metabolic syndrome, according to Ruiz.

Healz was born in 2020 by Jorge Ruiz and his partner, Dr. Antonio Hernández, although the majority of the capital is held by Ruiz. After setting up a comprehensive medicine clinic in Valencia, Ruiz realized that he required a lot of effort to treat patients with complicated pathologies at that center, caused above all by unhealthy lifestyles. It was then that both launched the technological platform they use.

The Valencian company obtained the CE marking for its sanitary technology in December 2022

The Valencian company obtained the CE marking for its sanitary technology in December 2022 and in January they began the commercial launch of their product. Healz already has 300 clients and the goal for 2023 is to reach a thousand patients.

In the coming months, the Spanish company will open the market in Latin America, Mexico, and Chile, countries in which it expects to have between 1,500 patients and 2,000 patients per month after undertaking pilot tests. Likewise, in a period of twelve months and after having recently started commercial activity, the company’s forecast is to reach an income of more than two million euros.

__

(Featured image by Themil via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.